Liver
Hepatocellular carcinoma
The primary cancer of liver cells, arising mostly in chronic hepatitis and cirrhosis; bulky, bile-stained and often with satellite nodules, it invades portal vein branches and is usually found late.
Causes and risk factors
- Chronic viral hepatitis B and C (the commonest causes worldwide)
- Chronic alcohol abuse
- Aflatoxin, haemochromatosis, α1-antitrypsin deficiency and NAFLD
Gross pathology
- A large, bulky, greenish (bile-containing) tumour with satellite nodules, or multifocal masses.
- Prone to necrosis and haemorrhage.
Under the microscope
- Well-differentiated tumour cells resembling large, irregular liver cells in wide, irregular cords.
- No normal lobules: portal triads and central veins are absent; a dysplastic nodule can be the precursor.
How it develops
- Chronic injury and regeneration in cirrhosis increase liver cell turnover.
- A dysplastic nodule appears, with atypia and lost architecture.
- Carcinoma develops and spreads within the liver and into portal vein branches.
Complications
- Raised serum α-fetoprotein
- Haemoperitoneum from bleeding at the capsule
- Malaise, fatigue, weight loss, pain and abdominal enlargement
- Most patients survive less than a year, as it is rarely found early
Investigations
- Alpha-fetoprotein (AFP)
- Raised in many cases.
- Multiphase CT or MRI
- A mass that enhances in the arterial phase and washes out later; may show portal vein invasion.
- Surveillance ultrasound
- Repeated in cirrhosis to detect tumours early.
- Biopsy
- When imaging is not diagnostic: malignant hepatocytes in thickened trabeculae.
Drug treatment
- Anti-angiogenic tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib): Small molecules that block the receptors through which tumours recruit new blood vessels; used in advanced renal cell carcinoma.
- Immune checkpoint inhibitors: Antibodies that release the brakes on T cells (PD-1, PD-L1, CTLA-4) so the immune system attacks the tumour; they transformed melanoma, renal cell, lung and liver cancer and Hodgkin lymphoma, but can trigger autoimmune damage to any organ.
Anatomy involved
Connected topics
Written from
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 8, The Liver and Biliary Tract, pp. 239–240, figs 8-48 to 8-51
Educational reference. Not medical advice, diagnosis or treatment.